Mary N. Carrington
Cancer and Inflammation Program
National Cancer Institute
United States of America
Dr. Carrington obtained her Ph.D. at Iowa State University in the Immunobiology Department. She performed her postdoctoral studies in the departments of Immunology and Microbiology at Duke University and the University of North Carolina. Prior to her current appointment, she was a faculty member in the Immunology Department at Duke University. Dr. Carrington is a senior principal scientist with Leidos Biomedical, Inc. and head of the HLA Immunogenetics Section in the Cancer and Inflammation Program. Her lab focuses on the genetic basis for resistance/susceptibility to disease conferred by immunogenetic variation.
1) Immunogenetics, 2) Genetic epidemiology, 3) HIV/AIDS, 4) Human leukocyte antigens (HLA), 5) Killer cell immunoglobulin-like receptors (KIR) 6) Epidemiology, 7) Genetics and Genomics, 8) Immunology 9) The genetic basis for resistance or susceptibility to disease conferred by polymorphic immune response loci, 10) impact of HLA gene expression in disease, the molecular mechanism regulating expression levels, and the functional basis for the effect of differential expression on disease outcome.